BioSpace News Archive

Sorrento Therapeutics, Inc. (Nasdaq: SRNE, “Sorrento”) today announced the peer-reviewed publication of significant results from a pivotal study of abivertinib on 227 heavily pretreated NSCLC patients in the journal Clinical Cancer Research, authored by Dr. Yi-Long Wu, distinguished professor of Guangdong Lung Cancer Institute, awardee of the prestigious “International Association for the Study of Lung Cancer (IASLC) Scientific Award” in 2017, and the principal investigator of the study.

Treadwell Therapeutics, today announced a presentation for the Company’s CFI-402411 program, an oral, first-in-class inhibitor of Hematopoietic Progenitor Kinase 1 (HPK1) a negative regulator of immune cell activation, at the 36th Society for Immunotherapy of Cancer (SITC) Annual Meeting.

Nxt-ID, Inc., provider of personal emergency response systems, health communications devices and IoT technology, announced financial and operations results for the third quarter and nine-month period ended September 30, 2021.

Actym Therapeutics today announced that ACTM-838 has been selected as a lead clinical development candidate for the treatment of solid tumors.

DURECT Corporation announced the presentation of data at the American Association for The Study of Liver Diseases The Liver Meeting® 2021 showcasing an increase of hospitalizations for alcohol-associated hepatitis in the U.S. of approximately 19% or approximately 4.8% per year between 2015 and 2018.

InterVenn Biosciences, the leader in glycoproteomics, presented results today on a predictive signature capable of identifying non-small cell lung cancer patients that will benefit most from immune checkpoint inhibitors

Avenue Therapeutics, Inc., a company focused on the development of intravenous tramadol for the U.S. market, announced the closing of its public offering of 1,946,787 shares of common stock at a public offering price of $1.34.

InterVenn Biosciences requests that their press release NewsItemId: 20211112005301 “InterVenn Presents Results Detailing Glycoproteomic Signature Predictive of Response to Immune Checkpoint Inhibitor Treatment in Advanced Non-Small Cell Lung Cancer at American Society for Immunotherapy of Cancer” be killed.

NRx Pharmaceuticals, a clinical-stage, biopharmaceutical company, announced its Chairman of the Board and Chief Executive Officer, Jonathan Javitt, will be presenting updates to the Company’s business at the H.C. Wainwright 7th Annual Israel Virtual Conference.

Carisma Therapeutics Inc., presented today for the first time preliminary findings from the landmark Phase 1 multi-center clinical trial of CT-0508, a human epidermal growth factor receptor 2 (HER2) targeted chimeric antigen receptor macrophage (CAR-M) .